An arteriovenous malformation (AVM) is an abnormal tangle of blood vessels where arteries connect directly to veins, bypassing the tiny capillaries that normally sit between them. AVMs affect roughly 18 out of every 100,000 adults, and about 1 in 100,000 people are newly diagnosed each year. Most AVMs form in the brain or spinal cord, though they can develop anywhere in the body. They’re present from birth in most cases, growing silently for years or even decades before causing symptoms.
How Normal Blood Flow Goes Wrong
In a healthy circulatory system, blood travels from the heart through arteries, then passes through a network of capillaries before returning through veins. Capillaries are essential: their thin walls slow blood flow and allow oxygen and nutrients to pass into surrounding tissue. They also absorb the high pressure coming from arteries so that veins, which have thinner, more delicate walls, only handle low-pressure blood.
An AVM eliminates that buffer zone entirely. Arterial blood rushes directly into veins at full force, creating what doctors call a high-flow, low-resistance shunt. The veins aren’t built to handle this pressure. Over time, they stretch, weaken, and become “arterialized,” developing thicker walls but never truly adapting to the strain. This elevated pressure can damage surrounding brain tissue in two ways: the physical mass of swollen vessels pushes against nearby structures, and the rerouted blood flow can starve adjacent tissue of oxygen, causing a form of localized ischemia.
What Causes AVMs
Most AVMs appear to develop during fetal growth when blood vessels are first forming, though the exact trigger remains poorly understood. They are not caused by anything a parent did during pregnancy.
A small but important subset of AVMs is linked to a genetic condition called hereditary hemorrhagic telangiectasia (HHT). People with HHT carry mutations in genes that control how blood vessels grow and maintain their walls. These genes all belong to a single signaling pathway involved in vessel development. Roughly 52% of HHT cases trace to one gene, 44% to another, and about 1% to a third. People with HHT often develop multiple AVMs in the lungs, brain, and liver rather than a single isolated one. If you have a family history of frequent nosebleeds, visible red spots on the skin or lips, or AVMs in multiple organs, HHT testing may be relevant.
Symptoms and Warning Signs
Many AVMs produce no symptoms at all and are discovered incidentally during imaging for something else. When symptoms do appear, they depend heavily on where the AVM sits and how large it is.
For brain AVMs, common symptoms include seizures, headaches concentrated in one area of the head, and muscle weakness or numbness on one side of the body. More serious presentations can involve sudden severe headache, vision loss, difficulty speaking, confusion, and trouble walking. In spinal AVMs, symptoms tend to develop gradually and may include progressive weakness, tingling, or problems with bladder and bowel control as the swollen vessels press on the spinal cord.
The most dangerous event is hemorrhage. When the weakened vein walls finally give way under sustained arterial pressure, the resulting bleed can be life-threatening, particularly in the brain.
Hemorrhage Risk Over Time
The overall risk of an AVM bleeding is about 2% to 4% per year. That number shifts depending on the AVM’s history. For AVMs that have never bled, the annual risk sits around 2%. For those that have already ruptured once, the rate climbs to roughly 4.5% per year, with the highest risk concentrated in the first year after the initial bleed.
These percentages sound small in any single year, but they compound over a lifetime. A 25-year-old with an unruptured AVM faces decades of cumulative exposure to that annual risk, which is why treatment decisions often weigh a person’s age and life expectancy heavily.
How AVMs Are Diagnosed
AVMs are typically identified using two complementary imaging techniques. Magnetic resonance angiography (MRA), a specialized form of MRI, provides detailed three-dimensional images of the malformation and surrounding brain tissue. It’s excellent for defining the boundaries of an AVM and assessing its relationship to critical structures.
Digital subtraction angiography (DSA), a catheter-based procedure that produces real-time X-ray images of blood flow, remains essential because of its extremely high sensitivity. It catches parts of the AVM that MRA might miss, particularly the feeding arteries and draining veins. The tradeoff is that DSA is two-dimensional, so it can sometimes overestimate the extent of the malformation. In practice, both are used together: MRA maps the anatomy in three dimensions while DSA confirms every vessel involved.
Grading an AVM’s Complexity
Once diagnosed, brain AVMs are graded using the Spetzler-Martin scale, a scoring system developed in 1986 that remains the most widely used classification tool. It assigns points based on three factors:
- Size: Under 3 cm scores 1 point, 3 to 6 cm scores 2, and over 6 cm scores 3.
- Location: AVMs in “eloquent” brain areas (regions controlling speech, movement, vision, or other critical functions) score 1 point. Non-eloquent locations score 0.
- Venous drainage: Deep drainage patterns score 1 point; superficial drainage scores 0.
The total ranges from 1 (simplest) to 5 (most complex). Lower grades carry significantly better surgical outcomes. In one analysis, the risk of complications was 0.6% for AVMs in non-eloquent areas compared to 9.5% in eloquent regions. This grading directly shapes treatment recommendations.
Treatment: Surgery
Microsurgical resection, where a neurosurgeon physically removes the tangle of abnormal vessels, is considered the gold standard for low-grade AVMs. It offers the highest chance of immediate, complete cure. In a recent study of surgical outcomes, 87% of patients with low-grade AVMs achieved good functional recovery by nine months after surgery. For high-grade AVMs, that number dropped to 50%.
Surgery carries real risks, including post-operative bleeding (about 11% of cases) and infection. Recovery involves a hospital stay and a period of rehabilitation, particularly if the AVM was in or near areas controlling movement or speech. The main advantage of surgery is that once the AVM is removed, the risk of hemorrhage drops to zero immediately.
Treatment: Radiosurgery
Stereotactic radiosurgery uses highly focused beams of radiation to gradually close off an AVM without any incision. It’s best suited for smaller AVMs (under 3 cm) or those located in areas too deep or too functionally important for open surgery.
The key distinction from surgery is the timeline. Radiosurgery doesn’t eliminate the AVM immediately. The treated vessels slowly scar and close over months to years. The median time to complete closure is about 36 months, though it can take anywhere from 7 months to over 13 years. During that waiting period, the AVM can still bleed.
Success rates depend on grade: 85% obliteration at five years for grade I and II AVMs, dropping to around 62% for grades IV and V. For carefully selected small AVMs, obliteration rates reach 80% to 90%. After treatment, patients undergo MRI every six months to track progress, with annual monitoring once closure is confirmed.
Treatment: Embolization
Embolization is a catheter-based procedure where a doctor threads a thin tube through the blood vessels and injects a liquid glue-like substance directly into the AVM. This material hardens inside the abnormal vessels, blocking blood flow through them. The two most commonly used agents are a polymer that precipitates on contact with blood and a fast-setting surgical glue.
Embolization is rarely used as a standalone cure. More often, it serves as a first step to shrink a large AVM before surgery or radiosurgery, reducing blood flow through the malformation and making the subsequent treatment safer and more effective. In some cases, it’s used to target a specific weak point in the AVM that’s at high risk of bleeding, buying time before definitive treatment.
Choosing a Treatment Approach
Treatment decisions for AVMs are highly individualized. A small, superficial, low-grade AVM in a young patient is a strong candidate for surgery, which offers an immediate cure. A deep, eloquent-area AVM might be better addressed with radiosurgery, accepting the slower timeline in exchange for avoiding the risks of open brain surgery. Large, complex AVMs often require a staged combination of embolization followed by surgery or radiosurgery.
For some patients, particularly older adults with unruptured AVMs, careful observation with regular imaging may be the most reasonable path. The ARUBA trial, a major randomized study, found that unruptured AVMs managed conservatively had a hemorrhage rate of about 2.2% per year. When treatment risks are significant and life expectancy is shorter, that annual risk may be acceptable compared to the upfront dangers of intervention. The decision always balances the cumulative lifetime risk of bleeding against the immediate risks of whichever treatment is chosen.